Abbott Laboratories COVID-19 Testing revenue
COVID-19 Testing revenue at Abbott Laboratories came to $69.0M for the quarter to 30 Sep 2025, down 74.0% from a year earlier.
As Abbott Laboratories reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 29 Oct 2025.
By quarter
| Period ending | COVID-19 Testing revenue | Change on a year | Filed |
|---|---|---|---|
| 30 Sep 2025 | $69.0M | down 74.0% | 29 Oct 2025 |
| 30 Jun 2025 | $55.0M | down 46.1% | 30 Jul 2025 |
| 31 Dec 2024 | $176.0M | down 41.3% | 21 Feb 2025 |
| 30 Sep 2024 | $265.0M | down 13.1% | 31 Oct 2024 |
| 30 Jun 2024 | $102.0M | down 61.2% | 31 Jul 2024 |
| 31 Mar 2024 | $204.0M | down 72.1% | 2 May 2024 |
| 31 Dec 2023 | $300.0M | — | 16 Feb 2024 |
| 30 Sep 2023 | $305.0M | — | 1 Nov 2023 |
| 30 Jun 2023 | $263.0M | — | 3 Aug 2023 |
| 31 Mar 2023 | $730.0M | — | 4 May 2023 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Abbott Laboratories: Diabetes Care revenue · Core Laboratory revenue · Adult Nutritionals revenue · Key Emerging Markets revenue · Pediatric Nutritionals revenue · Cancer Diagnostics revenue · Rapid and Molecular revenue · Electrophysiology revenue · Vascular revenue · Rhythm Management revenue · Rapid Diagnostics revenue · Structural Heart revenue · Heart Failure revenue · Neuromodulation revenue · Point of Care revenue · Molecular revenue · Medical Devices revenue · Diagnostic Products revenue · Nutritional Products revenue · Established Pharmaceuticals revenue · financial statements
Every KPI and segment of ABT, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
